Hematological adverse events in the management of glioblastoma.
Catherine R GarciaZin W MyintRani JayswalChi WangRachael M MorganAllison R ButtsHeidi L WeissJohn L VillanoPublished in: Journal of neuro-oncology (2021)
HAEs are common during GBM treatment, and often involve more than one cell line (more likely during adjuvant therapy). HAEs may be associated with prolonged OS and PFS, particularly during adjuvant therapy. HAEs during chemoradiation was a protective factor for HAEs during adjuvant therapy.